High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference

被引:104
作者
Piketty, Marie-Liesse [1 ]
Prie, Dominique [1 ]
Sedel, Frederic [2 ]
Bernard, Delphine [2 ]
Hercend, Claude [1 ]
Chanson, Philippe [3 ,4 ]
Souberbielle, Jean-Claude [1 ]
机构
[1] GH Necker Enfants Malades, Serv Explorat Fonct, 149 Rue Sevres, F-75743 Paris 15, France
[2] MedDAY Pharmaceut, Paris, France
[3] Hop Univ Paris Sud, Hop Bicetre, AP HP, Serv Endocrinol & Malad Reprod, Le Kremlin Bicetre, France
[4] Univ Paris Sud, Univ Paris Saclay, Fac Med Paris Sud, INSERM 1185, Le Kremlin Bicetre, France
关键词
biotin; hyperthyroidism; immunoassay; interference; multiple sclerosis; PROGRESSIVE MULTIPLE-SCLEROSIS; GRAVES-DISEASE; VITAMIN-D; HYPERTHYROIDISM; IMMUNOASSAYS; TESTOSTERONE; FATIGUE; ASSAY; SERUM;
D O I
10.1515/cclm-2016-1183
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: High-dose biotin therapy is beneficial in progressive multiple sclerosis (MS) and is expected to be adopted by a large number of patients. Biotin therapy leads to analytical interference in many immunoassays that utilize streptavidin-biotin capture techniques, yielding skewed results that can mimic various endocrine disorders. We aimed at exploring this interference, to be able to remove biotin and avoid misleading results. Methods: We measured free triiodothyronine (fT3), free thyroxine (fT4), thyroid-stimulating hormone (TSH), parathyroid homrone (PTH), 25-hydroxyvitamin D (25OHD), follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin, C-peptide, cortisol (Roche Diagnostics assays), biotin and its main metabolites (liquid chromatography tandem mass spectrometry) in 23 plasmas from MS patients and healthy volunteers receiving high-dose biotin, and in 39 biotin-unsupplemented patients, before and after a simple procedure (designated N5) designed to remove biotin by means of streptavidincoated microparticles. We also assayed fT4, TSH and PTH in the 23 high-biotin plasmas using assays not employing streptavidin-biotin binding. Results: The biotin concentration ranged from 31.7 to 1160 mu g/L in the 23 high-biotin plasmas samples. After the N5 protocol, the biotin concentration was below the detection limit in all but two samples (8.3 and 27.6 mu g/L). Most hormones results were abnormal, but normalized after N5. All results with the alternative methods were normal except two slight PTH elevations. In the 39 biotinunsupplemented patients, the N5 protocol did not affect the results for any of the hormones, apart from an 8.4% decrease in PTH. Conclusions: We confirm that most streptavidin-biotin hormone immunoassays are affected by high biotin concentrations, leading to a risk of misdiagnosis. Our simple neutralization method efficiently suppresses biotin interference.
引用
收藏
页码:817 / 825
页数:9
相关论文
共 26 条
  • [21] False overt hyperthyroidism by interference in immunoassay
    Simo-Guerrero, Olga
    Gimenez-Perez, Gabriel
    Recasens-Gracia, Assumpta
    Villa-Blasco, Carme
    Castells-Fuste, Ignasi
    [J]. ENDOCRINOLOGIA Y NUTRICION, 2016, 63 (08): : 431 - 432
  • [22] Vitamin D and multiple sclerosisfrom epidemiology to prevention
    Sundstrom, P.
    Salzer, J.
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2015, 132 : 56 - 61
  • [23] MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
    Tourbah, Ayman
    Lebrun-Frenay, Christine
    Edan, Gilles
    Clanet, Michel
    Papeix, Caroline
    Vukusic, Sandra
    De Seze, Jerome
    Debouverie, Marc
    Gout, Olivier
    Clavelou, Pierre
    Defer, Gilles
    Lapland, David-Axel
    Moreau, Thibault
    Labauge, Pierre
    Brochet, Bruno
    Sedel, Frederic
    Pelletier, Jean
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (13) : 1719 - 1731
  • [24] More on Biotin Treatment Mimicking Graves' Disease
    Trambas, Christina M.
    Sikaris, Ken A.
    Lu, Zhong X.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (17) : 1698 - 1698
  • [25] Positive and negative interference in immunoassays following biotin ingestion: a pharmacokinetic study
    Wijeratne, Nilika G.
    Doery, James C. G.
    Lu, Zhong X.
    [J]. PATHOLOGY, 2012, 44 (07) : 674 - 675
  • [26] Biotin
    Zempleni, Janos
    Wijeratne, Subhashinee S. K.
    Hassan, Yousef I.
    [J]. BIOFACTORS, 2009, 35 (01) : 36 - 46